Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 52

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 52
---
 maintain sales and marketing capabilities, whether alone or with potential future 
 collaborators;                                                                                               |

S-8

| • |     | our plans to research, develop and commercialize our product candidates, including the timing of our ongoing 
 clinical trials;                                                                                             |

| • |     | our expectations regarding the size of target patient populations for our approved medicines and our product 
 candidates, if approved for commercial use, and any additional product candidates we may develop;            |

| • |     | the size and growth potential of the markets for our approved medicines and our product candidates, and our 
 ability to serve those markets;                                                                             |

| • |     | the rate and degree of market acceptance of our approved medicines and our product candidates, as well as 
 third-party payor coverage and reimbursement for our approved medicines and our product candidates;       |

| • |     | our ability to attract collaborators with development, regulatory and commercialization expertise; |

| • |     | our expectations regarding our ability to obtain, maintain, enforce and defend our intellectual property 
 protection for our approved medicines and our product candidates;                                        |

| • |     | governmental, regulatory and legal developments in the United States and foreign countries; |

| • |     | the performance of our third-party collaborators, suppliers and manufacturers; |

| • |     | the success of competing therapies that are or may become available; |

| • |     | our ability to attract and retain key scientific or management personnel; |

| • |     | our ability to timely obtain funding for our operations on favorable terms and strategically deploy that funding, 
 if and when obtained;                                                                                             |

| • |     | the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing; and |

| • |     | our anticipated use of the net proceeds from this offering. |

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for our management to predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any